Antisoma announces discontinuation of development of AS1402
(Thomson Reuters ONE) - 07 August 2009, London, UK, and Cambridge, MA: Antisoma plc (LSE:ASM; USOTC: ATSMY) today announces that the phase II trial of AS1402in breast cancer is to be discontinued. This follows a meeting of thetrial's Data Monitoring Committee (DMC) and a subsequent review ofthe data, which led the company to conclude that the trial would bevery unlikely to give sufficiently positive efficacy findings. Nosafety concerns were identified. Antisoma has no plans for furtherstudies of AS1402.Glyn Edwards, Antisoma's CEO, said "While AS1402 was an early stageproduct and therefore not an important contributor to our overallvalue, we are of course disappointed that the drug was not able toprovide benefit to breast cancer patients."Enquiries:Glyn Edwards, CEO +44 (0)20 3249 2144Antisoma plcMark Court/Lisa Baderoon/Rebecca Skye +44 (0)20 7466 5000DietrichBuchanan CommunicationsBrian Korb +1 646 378 2923The Trout GroupAbout AS1402AS1402 (huHMFG1, previously known also as R1550 and Therex) is ahumanised antibody against a form of MUC1 found on the surface ofvarious cancers. This study was a 110-patient phase II trial in womenreceiving first-line treatment for advanced breast cancer. Patientswere randomised to receive either AS1402 plus the hormone therapyletrozole or letrozole alone. Letrozole will continue to be madeavailable to patients. AS1402 was licensed by Antisoma from theImperial Cancer Research Technologies, the technology transfer arm ofthe Imperial Cancer Research Fund (now Cancer Research UK).About AntisomaAntisoma is a London Stock Exchange-listed biopharmaceutical companythat develops novel products for the treatment of cancer. The Companyhas operations in the UK and the US. Please visitwww.antisoma.com for further information about Antisoma.---END OF MESSAGE---This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 07.08.2009 - 08:01 Uhr
Sprache: Deutsch
News-ID 4472
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Antisoma announces discontinuation of development of AS1402"
steht unter der journalistisch-redaktionellen Verantwortung von
Antisoma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
